spherix global insights services Services
Special Report: Multi-Specialty Impact of COVID-192020-10-30T20:27:40+00:00

Special Topix: Multi-Specialty Impact of COVID-19 (US)

Special Topix: Multi-Specialty Impact of COVID-19 (US) is an ongoing series of monitoring evaluating the impact of COVID-19 on physicians and their practices – including, but not limited to, the utilization of telemedicine, at-risk patient groups, key concerns, support from industry, future changes in prescribing patterns, how practices are beginning to re-open, and what changes have been implemented as the new normal.

Specialty reports are available for dermatology, gastroenterology, nephrology, neurology, and rheumatology. Each wave consists of feedback gathered from 250 specialists (~50 per specialty), geographically dispersed across the US. The report is offered by specialty and includes high-level cross-specialty comparisons trended since mid-March. Waves 12 and 13 are set to publish in November and December.

Content Categories Include:

Impact on Practice

  • Financial impact on practice
  • Level of concern for patients
  • Covering for partners
  • Impact on clinical trial involvement
  • Policies against travel/meetings
  • Conference cancellations
  • Restricting non-essential visits (industry, etc.)
  • Implementation of telemedicine
  • Preparedness for widespread local outbreak
  • Appointment cancellations
  • Rescheduling routine visits
  • Overall impact to patient flow


  • Belief in being able to “flatten the curve”
  • Satisfaction with how government handling
  • Impact on supply chain for medication access
  • Access to care from ER/ED or urgent care facilities
  • Expected timeline for resolution?
  • Government performance
  • Willingness to try new products currently
  • Willingness to initiate patients on therapy or change treatment
  • Familiarity and anticipated utility of Gilead’s remdesivir against COVID-19

Interaction with Industry

  • Restrictions of in-person contact
  • Recent industry contact methods
  • Pharmaceutical industry support during outbreak
  • Pharmaceutical company most active in addressing COVID-19 at national level / within personal practice


  • Number requesting test
  • Level of risk among requesting patients
  • Number tested
  • Number of positive/negative among those tested
  • Logistics of testing
  • Barriers to testing

Information on COVID-19

  • Source(s) being used for your own information
  • Most valuable information sources
  • Contact with state health department
  • How informed physicians feel about COVID-19 testing, guidelines, and treatment


  • Percent at risk
  • Characteristics of most at risk
  • How well informed about true risks


  • Specialty, patient volume, practice type, practice location, infusion capabilities, and clinical trial participation
  • Nearby outbreak and related restrictions
  • Personal travel to EU or China in past three months

Specialty specific

  • In immune, use of IL-6 inhibitors
  • In MS, switching from or delaying next doses of immunosuppressant DMTs
  • In migraine, use of newly approved therapy or anti-CGRP monoclonal antibodies
  • In nephrology, impact in dialysis units

Get In Touch With Us

*Required fields

Read the Latest

Load More Posts
Go to Top